Episodios

  • Top Takeaways from 2025: Clinical Cardiology with Allen J. Taylor, MD, FACC

    Top Takeaways from 2025: Clinical Cardiology with Allen J. Taylor, MD, FACC
    Dec 11 2025
    In this interview, Allen J. Taylor, MD, FACC and Alison L. Bailey, MD FACC, discuss the Top Clinical Cardiology Takeaways from 2025 including trials SCOT-HEART 2, ALONE-AF, Launch-HTN, and more. Suggested Materials: 1. Kim D, Shim J, Choi EK, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025;334(14):1246-1254. doi:10.1001/jama.2025.14679 2. Lemesle G, Didier R, Steg PG, et al. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. N Engl J Med. 2025;393(16):1578-1588. doi:10.1056/NEJMoa2507532 3. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027 4. Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363-1374. doi:10.1056/NEJMoa2507109 5. Saxena M, Laffin L, Borghi C, et al. Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. JAMA. 2025;334(5):409-418. doi:10.1001/jama.2025.9413 6. McDermott M, Khaing PH, Meah MN, et al. CT Angiography, Healthy Lifestyle Behaviors, and Preventive Therapy: A Nested Substudy of the SCOT-HEART 2 Randomized Clinical Trial. JAMA Cardiol. 2025;10(8):841-850. doi:10.1001/jamacardio.2025.1763 Subscribe on Apple Podcasts | Subscribe to ACCEL
    Más Menos
    19 m
  • Top Takeaways from 2025: Interventional Cardiology with Deepak Bhatt, MD, MPH, MBA, FACC

    Top Takeaways from 2025: Interventional Cardiology with Deepak Bhatt, MD, MPH, MBA, FACC
    Dec 10 2025
    In this interview, Deepak Bhatt, MD, MPH, FACC and Alison L. Bailey, MD FACC, discuss the Top Interventional Cardiology Takeaways from 2025 including DanGer Shock trial, revascularization in STEMI, aspirin withdrawal after PCI, and more. Suggested Materials: 1. Møller JE, Beske RP, Engstrøm T, et al. Long-Term Outcomes of the DanGer Shock Trial. N Engl J Med. 2025;393(10):1037-1038. doi:10.1056/NEJMc2508284 2. Ueyama HA, Akita K, Kiyohara Y, et al. Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis. J Am Coll Cardiol. 2025;85(1):19-38. doi:10.1016/j.jacc.2024.09.1231 3. Généreux P, Schwartz A, Oldemeyer JB, et al. Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis. N Engl J Med. 2025;392(3):217-227. doi:10.1056/NEJMoa2405880 4. Guimarães PO, Franken M, Tavares CAM, et al. Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. N Engl J Med. Published online August 31, 2025. doi:10.1056/NEJMoa2507980 5. Valgimigli M, Choi KH, Giacoppo D, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025;406(10508):1091-1102. doi:10.1016/S0140-6736(25)01562-4 Subscribe on Apple Podcasts | Subscribe to ACCEL
    Más Menos
    17 m
  • PANTHER-P2Y12 Inhibitor or Aspirin moNoTHERapy as Secondary Prevention in Patients with CAD

    PANTHER-P2Y12 Inhibitor or Aspirin moNoTHERapy as Secondary Prevention in Patients with CAD
    Dec 9 2025
    he PANTHER study indicates that clopidogrel provides superior protection against major cardiovascular events compared to aspirin in patients with coronary artery disease, without increasing bleeding risk. This supports its use in individuals at higher risk of gastrointestinal complications, reinforcing current clinical preferences. Overall, these results could inform long-term treatment strategies and improve outcomes for millions of patients worldwide. In this interview, Alison L. Bailey, MD, FACC and Prof. Marco Valgimigli discuss "PANTHER-P2Y12 Inhibitor or Aspirin moNoTHERapy as Secondary Prevention in Patients with CAD". Suggested Materials: 1. Giacoppo D, Gragnano F, Watanabe H, et al. P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials. BMJ. 2025;389:e082561. Published 2025 Jun 4. doi:10.1136/bmj-2024-082561 2. Valgimigli M, Hong SJ, Gragnano F, et al. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024;404(10456):937-948. doi:10.1016/S0140-6736(24)01616-7 3. P2Y(12) Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AR, Zhao Q, Woodward M, Chiarito M, McFadden EP, Park KW, Kastrati A, Seljeflot I, Zhu Y, Windecker S, Kang J, Schunkert H, Arnesen H, Bhatt DL, Steg PG, Calabrò P, Pocock S, Mehran R, Valgimigli M; PANTHER Collaboration. J Am Coll Cardiol. 2023;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051 Subscribe on Apple Podcasts | Subscribe to ACCEL
    Más Menos
    12 m
  • ACCEL Lite: Top Takeaways from 2025: HF with Clyde Yancy MD, MSc, MACC

    ACCEL Lite: Top Takeaways from 2025: HF with Clyde Yancy MD, MSc, MACC
    Dec 4 2025
    In this interview, Clyde Yancy MD, MSc, MACC and Alison L. Bailey, MD FACC, discuss the Top Heart Failure Takeaways from 2025 including trials SUMMIT and BaxHTN, the ACC/AHA Blood Pressure Guidelines, and more. Suggested Materials: 1. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86(18):1567-1678. doi:10.1016/j.jacc.2025.05.007 2. Khan SS, Coresh J, Pencina MJ, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2023;148(24):1982-2004. doi:10.1161/CIR.0000000000001191 3. Yancy CW. Heart Failure: A Century View, From Failure to Function. Circulation. 2025;151(9):585-588. doi:10.1161/CIRCULATIONAHA.124.072249 4. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027 5. Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363-1374. doi:10.1056/NEJMoa2507109 Subscribe on Apple Podcasts | Subscribe to ACCEL
    Más Menos
    20 m
  • ACCEL Lite: Top Takeaways from 2025: CV Imaging with Amit R. Patel, MD, FACC

    ACCEL Lite: Top Takeaways from 2025: CV Imaging with Amit R. Patel, MD, FACC
    Dec 3 2025
    In this interview, Amit R. Patel, MD, FACC and Alison L. Bailey, MD FACC, discuss the Top Cardiovascular Imaging Takeaways from 2025 including myocardial fibroblast activation, photon-counting detector CT, the newly published ACC/AHA CT Advanced Training Statement, and more. Suggested Materials: 1. Nijveldt R, Maeng M, Beijnink CWH, et al. Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction. N Engl J Med. Published online October 28, 2025. doi:10.1056/NEJMoa2512918 2. Barton AK, Craig NJ, Loganath K, et al. Myocardial Fibroblast Activation After Acute Myocardial Infarction: A Positron Emission Tomography and Magnetic Resonance Study. J Am Coll Cardiol. 2025;85(6):578-591. doi:10.1016/j.jacc.2024.10.103 3. Sakai K, Shin D, Singh M, et al. Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease. J Am Coll Cardiol. 2025;85(4):339-348. doi:10.1016/j.jacc.2024.10.069 4. Baldassarre LA, Mendes LA, Blankstein R, et al. 2025 ACC/AHA/ASE/ASNC/SCCT/SCMR Advanced Training Statement on Advanced Cardiovascular Imaging: A Report of the ACC Competency Management Committee. J Am Coll Cardiol. Published online November 18, 2025. doi:10.1016/j.jacc.2025.07.036 5. Sahashi Y, Ieki H, Yuan V, et al. Artificial Intelligence Automation of Echocardiographic Measurements. J Am Coll Cardiol. 2025;86(13):964-978. doi:10.1016/j.jacc.2025.07.053 Subscribe on Apple Podcasts | Subscribe to ACCEL
    Más Menos
    15 m
  • C-Reactive Protein and CV Risk in the General Population

    C-Reactive Protein and CV Risk in the General Population
    Dec 2 2025

    Inflammation is a key contributor to cardiovascular disease (CVD), influencing both its onset and progression. High-sensitivity C-reactive protein (hsCRP) serves as a reliable biomarker for detecting systemic inflammation and assessing cardiovascular risk. Recognizing the role of inflammation helps refine risk stratification and guide preventive strategies in the general population.

    In this interview, Nanette Kass Wenger MD, MACC and Prof. Dr. Florian Kahles, MD discuss "C-Reactive Protein and CV Risk in the General Population".

    SUGGESTED MATERIALS:

    1. Amezcua-Castillo E, González-Pacheco H, Sáenz-San Martín A, et al. C-Reactive Protein: The Quintessential Marker of Systemic Inflammation in Coronary Artery Disease-Advancing toward Precision Medicine. Biomedicines. 2023;11(9):2444. Published 2023 Sep 2. doi:10.3390/biomedicines11092444

    Subscribe on Apple Podcasts | Subscribe to ACCEL

    Más Menos
    9 m
  • ALONE-AF: Discontinuing Long-Term Oral Anticoagulation After Successful AFib Ablation

    ALONE-AF: Discontinuing Long-Term Oral Anticoagulation After Successful AFib Ablation
    Nov 25 2025

    The ALONE-AF study examined outcomes in atrial fibrillation (AF) patients who remained free of recurrence following catheter ablation. Researchers found that discontinuing oral anticoagulation (OAC) was associated with a lower risk of stroke, systemic embolism, or major bleeding compared to continued OAC. These findings, presented at the ESC Congress 2025, suggest that stopping OAC may offer a safer long-term strategy for select post-ablation AF patients. This could mark a meaningful shift in how clinicians approach anticoagulation management in this population.

    In this interview, Dhanunjaya "DJ" Lakkireddy MBBS, FACC and Boyoung Joung, MD, PhD discuss "ALONE-AF: Discontinuing Long-Term Oral Anticoagulation After Successful AFib Ablation".

    SUGGESTED MATERIALS:

    1. New data on oral anticoagulation after successful ablation of atrial fibrillation (escardio.org website). 2025. Available at: https://www.escardio.org/The-ESC/Press-Office/Press-releases/New-data-on-oral-anticoagulation-after-successful-ablation-of-atrial-fibrillation#. Accessed 11/9/25.

    Subscribe on Apple Podcasts | Subscribe to ACCEL

    Más Menos
    12 m
  • How Does Imaging Guide Management in Patients with Obesity?

    How Does Imaging Guide Management in Patients with Obesity?
    Nov 18 2025

    Imaging is a powerful tool in managing obesity, helping clinicians visualize fat distribution and detect complications like fatty liver disease or heart issues. Advanced techniques like magnetic resonance imaging (MRI) and computed tomography (CT) scans guide personalized treatment plans and monitor progress over time. Despite challenges with equipment limitations, innovations like artificial intelligence and specialized scanners are making imaging more accessible and accurate for patients with obesity.

    In this interview, W. Douglas Weaver MD, MACC and Mouaz H. Al-Mallah, MD, FACC discuss "How Does Imaging Guide Management in Patients with Obesity?"

    Subscribe on Apple Podcasts

    Más Menos
    10 m